A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer

BACKGROUND: Niclosamide, an FDA-approved anti-helminthic drug, has activity in preclinical models of castration-resistant prostate cancer (CRPC). Potential mechanisms of action include degrading constitutively active androgen receptor splice variants (AR-Vs) or inhibiting other drug-resistance pathw...

Descripción completa

Detalles Bibliográficos
Autores principales: Schweizer, Michael T., Haugk, Kathleen, McKiernan, Jožefa S., Gulati, Roman, Cheng, Heather H., Maes, Jessica L., Dumpit, Ruth F., Nelson, Peter S., Montgomery, Bruce, McCune, Jeannine S., Plymate, Stephen R., Yu, Evan Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983471/
https://www.ncbi.nlm.nih.gov/pubmed/29856824
http://dx.doi.org/10.1371/journal.pone.0198389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983471/
https://www.ncbi.nlm.nih.gov/pubmed/29856824
http://dx.doi.org/10.1371/journal.pone.0198389

Ejemplares similares